Retatrutide

Identity

Overview

Aliases

LY3437943, Reta, Triple G agonist

Topics

gip, glp-1, glucagon, metabolic, metabolism, weight management

Regulatory and product note

Separate approved-product evidence, research evidence, and supplier product claims.

Proposed mechanism

Proposed mechanism

Targets GLP-1, GIP, and glucagon receptor pathways involved in appetite, glycemic regulation, and energy/metabolic signaling.

Evidence

Evidence and limitations

This record keeps mechanisms, animal studies, human biomarkers, controlled clinical outcomes, safety data, and supplier documentation separate so claims are not flattened into one misleading score.

Research questions tracked

• What exact molecule, route, formulation, and outcome were studied?
• Is the evidence mechanistic, animal, early human, or controlled clinical evidence?
• Does the commercial product match the studied material and documentation?

Key findings and boundaries

• Evidence strength changes by outcome and study type.
• Mechanism is useful context but not proof of clinical benefit.
• Supplier claims require separate documentation review.

Important gaps

• Long-term human safety and real-world product quality are often incomplete.
• Claims can exceed the route, formulation, and population studied.

Safety and unknowns

Safety and unknowns

Safety remains investigational. Trial data should not be transferred to gray-market products sold as Reta or GLP-3.

• Known and plausible adverse effects must be separated from product-quality risks.
• Injectable or research-use products add sterility, endotoxin, impurity, and handling concerns.

Testing & COAs

Testing and COAs

An observed COA may support specific laboratory findings. It does not by itself prove clinical benefit, safety, legality, sterility or suitability.

• Identity, assay/purity, batch matching, lab identity, and test date should be visible.
• COAs do not prove clinical effectiveness, legal status, or suitability for use.